View More Recent Stories

Mar 26, 2025 05:58AM BMO Capital Reiterates Outperform Rating on Dyne Therapeutics (DYN)

Mar 20, 2025 04:25PM Dyne Therapeutics (DYN) PT Lowered to $17 at JPMorgan

Mar 20, 2025 04:11PM Dyne Therapeutics (DYN) Announces Appointment of Erick J. Lucera as Chief Financial Officer

Mar 17, 2025 09:39AM H.C. Wainwright Reiterates Buy Rating on Dyne Therapeutics (DYN)

Mar 17, 2025 08:08AM Piper Sandler Reiterates Overweight on Dyne Therapeutics (DYN) as 'DYNE-251 Continues to DELIVER'

Mar 17, 2025 07:56AM Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN)

Mar 17, 2025 07:53AM Chardan Capital Markets Reiterates Buy Rating on Dyne Therapeutics (DYN)

Mar 11, 2025 04:11PM BMO Capital Starts Dyne Therapeutics (DYN) at Outperform

Mar 7, 2025 07:08AM Scotiabank Starts Dyne Therapeutics (DYN) at Sector Outperform

Feb 28, 2025 07:14AM Dyne Therapeutics (DYN) PT Lowered to $46 at H.C. Wainwright

Feb 28, 2025 06:47AM Dyne Therapeutics (DYN) PT Lowered to $48 at Piper Sandler

Jan 21, 2025 11:51AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN), PT $60

Jan 21, 2025 07:30AM Dyne Therapeutics (DYN) Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Jan 10, 2025 11:47AM Dyne Therapeutics Inc. (DYN) Reports New Clinical Data Showing Impact on Multiple Measures of Myotonic Dystrophy Type 1

Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'

Jan 2, 2025 07:17AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)

Dec 30, 2024 11:56AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)

Dec 12, 2024 04:08PM Baird Starts Dyne Therapeutics (DYN) at Outperform

Dec 2, 2024 12:37PM Piper Sandler highlights Dyne Therapeutics' (DYN) FORCE platform potential

Nov 26, 2024 05:13AM RBC Capital Starts Dyne Therapeutics (DYN) at Outperform

Nov 12, 2024 04:51PM Dynegy (DYN) Misses Q3 EPS by 25c

Oct 24, 2024 03:47AM JPMorgan Downgrades Dyne Therapeutics (DYN) to Neutral

Oct 9, 2024 07:30AM Dyne Therapeutics (DYN) Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

Sep 23, 2024 07:14AM Piper Sandler Reiterates Overweight Rating on Dyne Therapeutics (DYN)

Sep 3, 2024 11:45AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)

Sep 3, 2024 07:19AM Dyne Therapeutics Inc. (DYN) Declines 20% Following New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251

Sep 3, 2024 06:32AM Dyne Therapeutics Inc. (DYN) Appoints Doug Kerr as CMO

Sep 3, 2024 06:30AM Dyne Therapeutics Inc. (DYN) Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251

Aug 13, 2024 09:05AM Dyne Therapeutics (DYN) PT Raised to $53 at Piper Sandler

Aug 13, 2024 07:05AM Dynegy (DYN) Tops Q2 EPS by 2c

Aug 13, 2024 06:43AM Dyne Therapeutics (DYN) PT Raised to $55 at H.C. Wainwright

Aug 13, 2024 06:39AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)

Jun 24, 2024 12:31PM Jefferies Reiterates Buy Rating on Dyne Therapeutics (DYN)

Jun 24, 2024 07:32AM Dyne Therapeutics (DYN) Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

Jun 17, 2024 07:25AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)

View More Recent Stories